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Household screening and multidrug-resistant tuberculosis
Of the estimated half a million people who develop 
multidrug resistant (MDR) tuberculosis each year, less 
than 7% are diagnosed and only 1 in 5 of these have 
access to eﬀ  ective treatment.
1 To control this epidemic, 
dramatically increased eﬀ  orts are required to scale up 
case detection and treatment provision. In The Lancet, 
Mercedes Becerra and colleagues
2 report the yield of 
additional MDR tuberculosis diagnoses that are found 
by screening household contacts of index cases in Lima, 
Peru. This study—the largest of its kind to date—found 
that more than 2% of 4503 household contacts had 
active tuberculosis at the time the index case was 
diagnosed. Incident tuberculosis was also found at a 
rate of 1624 cases per 100 000 person-years over 4 years 
follow-up. These results support recommendations for 
active screening of household contacts of people with 
MDR tuberculosis,
3 and provide valuable lessons for other 
programmes striving to improve case detection and to 
reduce community transmission of MDR tuberculosis.
The drug-resistant tuberculosis programme in 
Lima was one of the ﬁ  rst to show the feasibility and 
eﬀ   ectiveness of second-line treatment for MDR 
tuberculosis in resource-limited settings.
4 However, the 
index patients included in this study were diagnosed 
in the early phases of the programme in Peru, and 
there were often considerable delays in diagnosis and 
treatment initiation. A previous study from the same 
cohort suggested that index patients often received 
several years of largely ineﬀ  ective, ﬁ  rst-line tuberculosis 
treatment before their diagnosis with MDR tuberculosis, 
and more than half also had bilateral cavitary disease at 
diagnosis.
5 These patients might have therefore been 
highly infectious for long periods before diagnosis, with 
household contacts among those at greatest risk.
6,7 
The high rate of disease transmission in Lima reminds 
us that, in poor settings, a substantial proportion 
of community transmission probably occurs before 
diagnosis of drug-resistant tuberculosis. Thus, early 
diagnosis and treatment initiation is crucial to reduce 
the risk of household and community transmission. 
Prevention of additional cases through early detection 
will be a much more eﬀ  ective  tuberculosis-control 
strategy, and less costly than treating cases as they 
emerge. Unfortunately, once diagnosed and started on 
treatment, many countries still emphasise the isolation 
of patients with MDR tuberculosis in hospitals as the 
main strategy to reduce community transmission. 
However, because of poor access to diagnostics for 
tuberculosis drug resistance, MDR tuberculosis diagnosis 
is often made only after ﬁ  rst-line regimens do not work. 
Poor accessibility and long delays for drug-sensitivity 
testing often mean that patients spend long periods in 
the community; furthermore, restricted hospitalisation 
capacity results in additional delays after diagnosis. 
These practical realities, which are common in most 
resource-limited settings, render patient isolation a 
relatively ineﬀ   ective infection control strategy, even 
before considering human rights concerns about 
involuntary detention.
8
In view of the high rate of incident cases after 
diagnosis, and the initiation of largely ambulatory 
treatment in Peru, could a substantial transmission 
risk remain after treatment initiation? Because of long 
latency, it is not possible to assess when infection 
occurred—active tuberculosis cases might emerge over 
a long period among infected household contacts, 
particularly because, in this setting, cases and contacts 
are largely HIV uninfected.
9 However, as shown in 
today’s study, the increased risk in incident contact 
cases associated with extremely drug-resistant (XDR) 
tuberculosis compared to MDR tuberculosis index cases 
might shed light on this question. Good treatment 
outcomes have been reported for patients with XDR 
tuberculosis in Peru and elsewhere.
5,10 However, in 
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European conference on chronic respiratory disease
On Oct 19, 2010, the European Respiratory 
Society (ERS) organised, at the request of the Belgian 
European Union (EU) Presidency, a preministerial 
conference on chronic respiratory disease. The conclusions 
were presented to the ministerial conference of the 27 EU 
Member States, which was devoted to chronic disease 
in general. This ﬁ   rst high-level conference on chronic 
respiratory disease was a valuable milestone in the Year 
of the Lung, declared by the Forum of International 
Respiratory Societies.
1 There was active participation by 
patients and their organisations (the European Federation 
of Allergy and Airway Diseases Patients’ Associations).
Peru, XDR patients were treated for tuberculosis 
before diagnosis with drug-resistant tuberculosis, for a 
median of almost 1 year longer than patients with MDR 
tuberculosis. Patients with XDR tuberculosis also took 
substantially longer to convert to negative sputum 
cultures, and had higher rates of treatment failure 
than did those with MDR tuberculosis.
5 These ﬁ  ndings 
suggest that in addition to an increased transmission 
risk before diagnosis and treatment initiation, XDR 
tuberculosis cases might also be associated with an 
increased transmission after treatment initiation. This 
increased risk after treatment is also likely to occur in 
any patients with drug-resistant tuberculosis who are 
slow to respond to treatment or in whom treatment 
does not work. Thus, the beneﬁ   ts of ambulatory 
treatment regarding increased capacity to provide 
treatment and improved outcomes might need to be 
balanced against the risk of ongoing transmission after 
treatment initiation.
Becerra and colleagues do not report whether index 
cases in these categories were responsible for an 
increased number of contact cases compared to patients 
who did well on treatment, and there might be too 
few cases for statistical discrimination. Nonetheless, 
these data highlight the need for both bacteriological 
monitoring of treatment eﬃ   cacy to detect potential 
treatment failures with possible hospitalisation at this 
point, and for the implementation of simple infection 
control measures in the homes of patients with drug-
resistant tuberculosis who are undergoing ambulatory 
treatment. Measures that include education on 
tuberculosis transmission, cough hygiene and, where 
possible, separate accommodation for patients until 
sputum cultures are negative, are certainly feasible in 
many settings and might be eﬀ  ective in mitigating 
the small transmission risk after diagnosis and 
treatment initiation.
11 
Becerra and colleagues’ results from Peru conﬁ  rm the 
previously suspected usefulness of contact screening, 
and highlight the urgent need for new diagnostics to 
enable early case detection and treatment initiation to 
prevent transmission. Along with previously published 
data, these data also suggest that ambulatory treatment 
is feasible and eﬀ  ective, albeit potentially associated 
with a risk of ongoing transmission.
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